Paul A. Volberding

28.9k total citations · 15 hit papers
191 papers, 19.8k citations indexed

About

Paul A. Volberding is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Paul A. Volberding has authored 191 papers receiving a total of 19.8k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Infectious Diseases, 58 papers in Virology and 46 papers in Epidemiology. Recurrent topics in Paul A. Volberding's work include HIV/AIDS Research and Interventions (91 papers), HIV/AIDS drug development and treatment (73 papers) and HIV Research and Treatment (58 papers). Paul A. Volberding is often cited by papers focused on HIV/AIDS Research and Interventions (91 papers), HIV/AIDS drug development and treatment (73 papers) and HIV Research and Treatment (58 papers). Paul A. Volberding collaborates with scholars based in United States, France and Australia. Paul A. Volberding's co-authors include Douglas D. Richman, Margaret A. Fischl, Donna M. Jacobsen, Melanie Thompson, Robert T. Schooley, Scott M. Hammer, Michael S. Saag, Martin Hirsch, Patrick Yéni and Joseph J. Eron and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Paul A. Volberding

186 papers receiving 18.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex

1987 2.3k citations Paul A. Volberding et al. profile →
Antiretroviral Treatment of Adult HIV Infection

2012 1.4k citations Joseph J. Eron, Donna M. Jacobsen et al. profile →
The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex

1987 975 citations Paul A. Volberding et al. profile →
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection

1990 951 citations Paul A. Volberding, Robert L. Murphy et al. profile →
Antiretroviral Therapy in Adults

2000 874 citations Donna M. Jacobsen, Michael S. Saag et al. profile →
Antiretroviral Therapy for HIV Infection in 1998

1998 837 citations Donna M. Jacobsen, Michael S. Saag et al. profile →
Antiretroviral Treatment of Adult HIV Infection

2008 832 citations Joseph J. Eron, Donna M. Jacobsen et al. profile →
Treatment for Adult HIV Infection

2006 767 citations Michael S. Saag, Donna M. Jacobsen et al. profile →
Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons

2004 674 citations Paul A. Volberding et al. profile →
Treatment for Adult HIV Infection

2004 601 citations Michael S. Saag, Donna M. Jacobsen et al. profile →
Antiretroviral Treatment of Adult HIV Infection

2010 595 citations Donna M. Jacobsen, Paul A. Volberding et al. profile →
Antiretroviral Treatment for Adult HIV Infection in 2002

2002 573 citations Donna M. Jacobsen, Michael S. Saag et al. profile →
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

2016 478 citations Michael S. Saag, Constance A. Benson et al. profile →
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

2018 401 citations Michael S. Saag, Constance A. Benson et al. profile →
Antiretroviral Treatment of Adult HIV Infection

2014 352 citations Joseph J. Eron, Constance A. Benson et al. profile →

Peers

Countries citing papers authored by Paul A. Volberding

Since Specialization

Citations

This map shows the geographic impact of Paul A. Volberding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul A. Volberding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul A. Volberding more than expected).

Fields of papers citing papers by Paul A. Volberding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul A. Volberding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul A. Volberding. The network helps show where Paul A. Volberding may publish in the future.

Co-authorship network of co-authors of Paul A. Volberding

This figure shows the co-authorship network connecting the top 25 collaborators of Paul A. Volberding. A scholar is included among the top collaborators of Paul A. Volberding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul A. Volberding. Paul A. Volberding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Autologous neutralizing antibodies increase with early antiretroviral therapy and shape HIV rebound after treatment interruption 2023 ·Science Translational Medicine ·(unknown), Behzad Etemad, Christy L. Lavine, (unknown), Yijia Li, James Regan, Colline Wong, Radwa Sharaf, Elizabeth Connick, Paul A. Volberding, Manish Sagar, Michael S. Seaman, Jonathan Z. Li	12
2	Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study 2020 ·BMJ Open ·Barbara N Harding, Bridget M. Whitney, Robin M. Nance, Heidi M. Crane, Greer Burkholder, Richard D. Moore, W. Christopher Mathews, Joseph J. Eron, Peter W. Hunt, Paul A. Volberding, Benigno Rodríguez, Kenneth H. Mayer, Michael S. Saag, Mari M. Kitahata, Susan R. Heckbert, Joseph A. Delaney	6
3	Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study 2020 ·BMC Infectious Diseases ·Barbara N Harding, Bridget M. Whitney, Robin M. Nance, (unknown), Heidi M. Crane, Greer Burkholder, Richard D. Moore, W. Christopher Mathews, Joseph J. Eron, Peter W. Hunt, Paul A. Volberding, Benigno Rodríguez, Kenneth H. Mayer, Michael S. Saag, Mari M. Kitahata, Susan R. Heckbert, Joseph A. Delaney	28
4	Implementing electronic substance use disorder and depression and anxiety screening and behavioral interventions in primary care clinics serving people with HIV: Protocol for the Promoting Access to Care Engagement (PACE) trial 2019 ·Contemporary Clinical Trials ·Derek D. Satre, Alexandra Anderson, Amy Leibowitz, (unknown), Sally Slome, Jason Flamm, C. Bradley Hare, Jennifer McNeely, Constance Weisner, Michael A. Horberg, Paul A. Volberding, Michael J. Silverberg	15
5	HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel. 2017 ·PubMed ·Paul A. Volberding	16
6	Exploring the Social Meaning of Curing HIV: A Qualitative Study of People Who Inject Drugs in Guangzhou, China 2014 ·AIDS Research and Human Retroviruses ·Carissa Chu, Fengshi Wu, Xi He, Qingyan Ma, Yu Cheng, Weiping Cai, Paul A. Volberding, Joseph D. Tucker	32
7	Sande's HIV/AIDS medicine, Medical management of AIDS 2012 2012 ·Elsevier eBooks ·Paul A. Volberding	9
8	Clinician Attitudes About Commercial Support of Continuing Medical Education 2011 ·Archives of Internal Medicine ·Jeffrey Tabas, Christy Boscardin, Donna M. Jacobsen, Michael A. Steinman, Paul A. Volberding, Robert B. Baron	26
9	The impact of HIV research on health outcome and healthcare policy 2011 ·Annals of Oncology ·Paul A. Volberding	4
10	Association Between Kidney Function and Albuminuria With Cardiovascular Events in HIV-Infected Persons 2010 ·Circulation ·Andy I. Choi, Yongmei Li, Steven G. Deeks, Carl Grünfeld, Paul A. Volberding, Michael G. Shlipak	140
11	Relationship Between Antiretroviral Prescribing Patterns and Treatment Guidelines in Treatment-Naive HIV-1-Infected US Veterans (1992-2004) 2006 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Mark Holodniy, John Hornberger, (unknown), (unknown), Thomas MaCurdy, (unknown), Paul A. Volberding, Lawrence Deyton	23
12	Baboon Bone-Marrow Xenotransplant in a Patient with Advanced HIV Disease: Case Report and 8-Year Follow-Up 2004 ·Transplantation ·Marian G. Michaels, Christina L. Kaufman, Paul A. Volberding, Phalguni Gupta, William M. Switzer, Walid Heneine, Paul Sandstrom, Lawrence D. Kaplan, Patrick S. Swift, Lloyd E. Damon, Suzanne T. Ildstad	10
13	The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults 2003 ·AIDS Research and Human Retroviruses ·J Michael Kilby, Jacob Lalezari, Joseph J. Eron, Margrit Carlson, Calvin Cohen, Roberto C. Arduino, (unknown), Joel E. Gallant, Paul A. Volberding, Robert L. Murphy, Fred Valentine, Michael S. Saag, (unknown), Prakash Sista, Alex Dusek	6
14	The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults 2002 ·AIDS Research and Human Retroviruses ·J Michael Kilby, Jacob Lalezari, Joseph J. Eron, Margrit Carlson, Calvin Cohen, Roberto C. Arduino, (unknown), Joel E. Gallant, Paul A. Volberding, Robert L. Murphy, Fred Valentine, Michael S. Saag, (unknown), Prakash Sista, Alex Dusek	152
15	What can modeling tell us about the threat of antiviral drug resistance? 2002 ·Current Opinion in Infectious Diseases ·Sally Blower, Paul A. Volberding	22
16	Toward a Definition of HIV Expertise: A Survey of Experienced HIV Physicians 2001 ·AIDS Patient Care and STDs ·Barbara Gerbert, James C. Moe, Michael S. Saag, Constance A. Benson, Donna M. Jacobsen, (unknown), (unknown), Amy Bronstone, Nona Caspers, Paul A. Volberding	13
17	Physicians' Transmission Prevention Assessment and Counseling Practices with Their HIV Positive Patients 1999 ·AIDS Education and Prevention ·Barbara Gerbert, Brandon Brown, Paul A. Volberding, Molly Cooke, Nona Caspers, Charles C. Love, Amy Bronstone	18
18	Protease inhibitors vindicated 1997 ·The Lancet ·Paul A. Volberding	2
19	A Phase I Study of HGP-30, a 30 Amino Acid Subunit of the Human Immunodeficiency Virus (HIV) p17 Synthetic Peptide Analogue Sub-unit Vaccine in Seronegative Subjects 1992 ·AIDS Research and Human Retroviruses ·(unknown), (unknown), (unknown), (unknown), Richard Stryker, Paul A. Volberding, Paul H. Naylor, (unknown), Prem S. Sarin, (unknown), (unknown), Peter N.R. Heseltine	18
20	Therapy of Acquired Immune Deficiency Syndrome with Recombinant Interleukin-2 1987 ·AIDS Research and Human Retroviruses ·Paul A. Volberding, Dewey J. Moody, (unknown), Edward C. Bradley, Constance B. Wofsy	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact